Get the Stockscreener App
0.7834
2.53%
-0.0203
Invivyd Inc stock is traded at $0.7834, with a volume of 2.01M.
It is down -2.53% in the last 24 hours and down -13.04% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$0.8037
Open:
$0.815
24h Volume:
2.01M
Relative Volume:
0.46
Market Cap:
$230.80M
Revenue:
$55.87M
Net Income/Loss:
$-77.60M
P/E Ratio:
-2.1962
EPS:
-0.3567
Net Cash Flow:
$-79.46M
1W Performance:
-12.35%
1M Performance:
-13.04%
6M Performance:
-68.91%
1Y Performance:
+5.10%
1-Day Range:
$0.7676
$0.815
1-Week Range:
$0.7676
$1.00
52-Week Range:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.7834 | 230.80M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK) - The Globe and Mail
Invivyd Inc updates investors on its antiviral pipeline as Nasdaq-listed biotech advances - ad-hoc-news.de
H.C. Wainwright reiterates Invivyd stock rating on regulatory path - Investing.com
H.C. Wainwright reiterates Invivyd stock rating on regulatory path By Investing.com - Investing.com South Africa
Invivyd Inc. (IVVD) Surges Nearly 13% as Bulls Test Key Resistance at $0.99Protective Put - dars.gov.et
Invivyd Inc stock and Covid antibody focus - Ad-hoc-news.de
IVVD Reiterated by BTIG -- Price Target Maintained at $10.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Healthcare Stocks Decline as Investors Rotate Away From Safety -- Healthcare Roundup - Moomoo
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval - Stocktwits
FDA to terminate PEMGARDA emergency authorization in June 2027 - Investing.com UK
Invivyd receives FDA termination notice for PEMGARDA EUA - grafa.com
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
Invivyd gets notice of Pemgarda EUA termination - MSN
Invivyd receives 12-month notice of EUA termination for PEMGARDA, plans FDA dialogue - TradingView
Invivyd, Inc. ประกาศแจ้งเรื่องการสิ้นสุดการอนุญาตใช้งานในกรณีฉุกเฉิน (EUA) สำหรับ PEMGARDA จาก FDA ภายหลังจากการยุติการประกาศสถานการณ์ฉุกเฉินด้านโควิด-19 ของกระทรวงสาธารณสุขและบริการมนุษย์แห่งสหรัฐฯ (HHS) - Moomoo
Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA - Stock Titan
Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down - Quiver Quantitative
PEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDA - Stock Titan
IVVDInvivyd Inc Short Interest - Finviz
Price to earnings forward of Invivyd, Inc. – NASDAQ:IVVD - TradingView
Price to sales forward of Invivyd, Inc. – NASDAQ:IVVD - TradingView
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Invivyd gives 14 new hires stock options worth 493,000 shares - Stock Titan
IVVD News | INVIVYD INC (NASDAQ:IVVD) - ChartMill
New Haven biotech company developing measles treatment as US cases top 2,100 - WFSB
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Value Benchmark Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Value Benchmark - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 3000 Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 3000E Value Benchmark - marketscreener.com
Invivyd, Inc. Actuals & Estimates (NASDAQ:IVVD) - TradingView
IVVD Forecast — Price Target — Prediction for 2027 - TradingView
Invivyd Shareholder Notice - TMX Newsfile
Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd, Inc. (IVVD) reports Q1 loss, lags revenue estimates - MSN
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311 - Insider Monkey
INVIVYD INC (IVVD) Stock Chart - ChartMill
Invivyd, Inc. spotlights new data for solid organ transplant recipients in Boston - Traders Union
Invivyd Inc (IVVD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Invivyd Inc (IVVD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Invivyd Inc (IVVD) Institutional Confidence - TradingKey
Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Invivyd completes Phase 3 COVID-19 antibody trial enrollment - grafa.com
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allen Robert D. III | Chief Scientific Officer |
Feb 17 '26 |
Sale |
1.54 |
18,189 |
28,004 |
133,879 |
| Green Julie | Chief Human Resources Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Green Julie | Chief Human Resources Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Duke William E. | Chief Financial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Duke William E. | Chief Financial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
117,717 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
138,681 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 18 '26 |
Sale |
1.58 |
34,939 |
55,127 |
181,736 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 17 '26 |
Sale |
1.54 |
32,771 |
50,454 |
216,675 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):